Skip to main content

and
Your search also matched 7 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis

Include preview-only content
  1. Article

    Open Access

    Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

    Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B (CHB) patients have an active liver disease with a high risk of progression to decompensated cirrhosis and hepatocellular carcinoma. The management st...

    Dengming He, Shimin Guo, Wen Chen, **anli Chen, Guohua Yan in BMC Infectious Diseases (2013)

  2. Article

    Open Access

    Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B

    The long-term goal of chronic hepatitis B (CHB) treatment is improvement of liver disease and prevention of cirrhosis. The aim of this study was to assess whether prolonged telbivudine treatment improves liver...

    **-Lin Hou, Daozheng Xu, Guangfeng Shi, Mobin Wan, Zachary Goodman in Advances in Therapy (2015)

  3. Article

    Open Access

    Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

    Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with...

    Jian Sun, Huiguo Ding, Guofeng Chen, Guiqiang Wang, Lai Wei in BMC Gastroenterology (2019)